January 2026
Altered states of consciousness
What January 2026's 20 new studies found, synthesized from the papers below. All Altered states of consciousness research →
The synthesis
Synthesized from 6 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Altered states of consciousness, non-ordinary states, altered consciousness, ASC, then ranked by relevance.
Research in January 2026 found that ayahuasca enhances functional connectivity in social brain networks (third visual pathway and mirror neuron systems) and reduces depressive symptoms for up to 180 days when combined with psychotherapeutic support. The intensity of altered states from psychedelics is influenced by a combination of pharmacological, individual, and contextual factors, with spiritual/therapeutic intentions and higher doses producing stronger effects. However, ibogaine carries a rare but serious risk of cardiac complications, and the field lacks standardized assessment methods for VR-induced altered states.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Ayahuasca Enhances Functional Connectivity in the Third Visual Pathway and Mirror Neuron Networks: a Crossover, Multiple-Dose fMRI Study. 2026 | crossover fMRI study | 12 | Supports | Ayahuasca (0.8 mg/kg DMT) significantly increased right pSTS connectivity and directed modulation from visual and mirror-neuron regions, with positive correlations to perspective-taking and improved social relationships at one-week follow-up. |
| Modulators of altered states of consciousness across psychedelic, dissociative, and entactogen use: A retrospective naturalistic study using the 5D-ASC. 2026 | retrospective naturalistic survey | 804 | Supports | Intensity of altered states was significantly predicted by spiritual/therapeutic intention, substance type (dissociative and serotonergic psychedelics > entactogens), higher dose, age, and gender. |
| Rare but relevant: Ibogaine and cardiovascular complications-prolonged QT interval and ventricular arrhythmias. 2026 | review | Opposes | Ibogaine presents a rare but clinically significant risk of QTc prolongation and ventricular arrhythmias, even at therapeutic doses and in individuals without pre-existing cardiac conditions. | |
| The therapeutic potential of ayahuasca in depression, generalized anxiety, and substance use disorders: modulation of the depressive burden in a longitudinal study. 2026 | longitudinal observational study | 280 | Supports | Ritualistic ayahuasca use combined with psychotherapeutic support led to significant reductions in depressive symptoms (MADRS) sustained for up to 180 days, though individual responses varied. |
| Measuring Altered States of Consciousness in Virtual Reality: A Systematic Analysis of Assessment Methods 2026 | systematic review | Unclear | VR-induced altered states can be systematically evaluated through multimodal techniques, but significant methodological inconsistencies and lack of standardization in experimental designs and measurement tools were identified. | |
| Micro-phenomenology of immersion and perceived presences under DMT. 2026 | micro-phenomenological study | 23 | Supports | Immersion under DMT follows a structured continuum from subtle to gross forms, with perceived presences emerging only after multisensory integration and 3D spatial characteristics develop. |
Ayahuasca (0.8 mg/kg DMT) significantly increased right pSTS connectivity and directed modulation from visual and mirror-neuron regions, with positive correlations to perspective-taking and improved social relationships at one-week follow-up.
crossover fMRI study Sample size: 12
Intensity of altered states was significantly predicted by spiritual/therapeutic intention, substance type (dissociative and serotonergic psychedelics > entactogens), higher dose, age, and gender.
retrospective naturalistic survey Sample size: 804
Ibogaine presents a rare but clinically significant risk of QTc prolongation and ventricular arrhythmias, even at therapeutic doses and in individuals without pre-existing cardiac conditions.
review
Ritualistic ayahuasca use combined with psychotherapeutic support led to significant reductions in depressive symptoms (MADRS) sustained for up to 180 days, though individual responses varied.
longitudinal observational study Sample size: 280
VR-induced altered states can be systematically evaluated through multimodal techniques, but significant methodological inconsistencies and lack of standardization in experimental designs and measurement tools were identified.
systematic review
Immersion under DMT follows a structured continuum from subtle to gross forms, with perceived presences emerging only after multisensory integration and 3D spatial characteristics develop.
micro-phenomenological study Sample size: 23
Points of agreement
- Ayahuasca and DMT produce measurable changes in brain connectivity and subjective experience, with effects linked to social cognition and therapeutic outcomes.
- The intensity of altered states is modulated by dose, intention, and individual factors such as age and gender.
- Psychedelic-assisted therapy shows promise for depression and substance use disorders when combined with psychotherapeutic support.
Conflicts
- No direct conflicts among the studies; however, the ibogaine safety review highlights a risk that contrasts with the generally positive therapeutic findings for other psychedelics.
- The VR review notes a lack of standardization, which may conflict with the goal of replicable assessment across studies.
Gaps
- Durability of effects beyond 180 days for ayahuasca therapy is not established.
- Blinding and placebo controls are lacking in most studies, limiting causal inference.
- Sample sizes are small for neuroimaging studies (n=12, n=23) and observational designs are prone to bias.
- Standardized assessment tools for VR-induced altered states are missing.
- Cardiac safety data for ibogaine are based on case reports rather than controlled trials.
- The role of CYP2D6 genotyping in ibogaine safety is suggested but not empirically tested in the provided studies.